Table 2.

Therapeutic evaluation according to AML subtype with KIT mutation in TARGET

	With AML1::ETO and KIT mutation	Without AML1::ETO but with KIT mutation	P value
Course 1
Bone marrow			0.35
CR	78.6% (22/28)	90.6% (29/32)
Not CR	21.4% (6/28)	9.4% (3/32)
MRD			0.05
Yes	30.0% (6/20)	4.0% (1/25)
No	70.0% (14/20)	96.0% (24/25)
Course 2
Bone marrow			0.48
CR	96.4% (27/28)	100.0% (31/31)
Not CR	3.6% (1/28)	0.0% (0/31)
MRD			0.44
Yes	5.0% (1/20)	0.0% (0/25)
No	95.0% (19/20)	100.0% (25/25)

P values were analyzed by the Chi-Square Test, compared with AML1::ETO and KIT mutation group

CR Complete remission, MRD Minimal residual disease